Ancora Advisors’s Outlook Therapeutics OTLK Stock Holding History

Ancora Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.75K	Hold	1,100	–	–	﹤0.01%	1797
2026 Q1	$226	Hold	1,100	–	–	﹤0.01%	2330
2025 Q4	$1.74K	Hold	1,100	–	–	﹤0.01%	2155
2025 Q3	$1.17K	Hold	1,100	–	–	﹤0.01%	1754
2025 Q2	$1.76K	Hold	1,100	–	–	﹤0.01%	1669
2025 Q1	$1.34K	Hold	1,100	–	–	﹤0.01%	1557
2024 Q4	$2.08K	Sell	1,100 -5,000	-82%	-$20.6K	﹤0.01%	1561
2024 Q3	$32.6K	Hold	6,100	–	–	﹤0.01%	1093
2024 Q2	$45K	Hold	6,100	–	–	﹤0.01%	971
2024 Q1	$72.8K	Hold	6,100	–	–	﹤0.01%	870
2023 Q4	$48.1K	Buy	6,100 +5,000	+455%	+$42.3K	﹤0.01%	954
2023 Q3	$4.86K	Sell	1,100 -4,325	-80%	-$95.7K	﹤0.01%	1396
2023 Q2	$189K	Hold	5,425	–	–	0.01%	664
2023 Q1	$118K	Hold	5,425	–	–	﹤0.01%	747
2022 Q4	$117K	Hold	5,425	–	–	﹤0.01%	792
2022 Q3	$132K	Buy	5,425 +4,325	+393%	+$101K	﹤0.01%	830
2022 Q2	$22K	Buy	+1,100	New	+$31.6K	﹤0.01%	1411

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GWM

Gilpin Wealth Management Denver, Colorado $145M AUM

Ancora Advisors's OTLK Position: Q2 2026 in Review

Ancora Advisors held its Outlook Therapeutics (OTLK) position steady in Q2 2026 at 1,100 shares worth $1.75K. The position accounts for ﹤0.01% of the portfolio, ranked #1797.

Ancora Advisors first reported a position in OTLK in Q2 2022 and has held it in 17 quarters since. The position peaked at $189K in Q2 2023. 69 funds tracked by Wall St. Rank hold OTLK as of Q2 2026.

Ancora Advisors held 1,100 shares of Outlook Therapeutics worth $1.75K as of Q2 2026.
Ancora Advisors left its Outlook Therapeutics share count unchanged in Q2 2026.
Outlook Therapeutics made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #1797 holding.
Ancora Advisors first reported a position in Outlook Therapeutics in Q2 2022 and has held it in 17 quarters since.
Ancora Advisors's Outlook Therapeutics position peaked at $189K in Q2 2023.
69 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.